News | September 24, 2025
Alkem launches pertuzumab biosimilar ‘Pertuza’ for treatment of HER2-positive breast cancer
Alkem's Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab
Alkem's Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab
The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
Encouraging early detection and breaking the silence around men’s health
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
The company has received approval from DCGI to begin patient enrolment and dosing in the country
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
Subscribe To Our Newsletter & Stay Updated
